Literature DB >> 34362474

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders.

A Bayas1, A Berthele2, B Hemmer3, C Warnke4, B Wildemann5.   

Abstract

Entities:  

Year:  2021        PMID： 34362474     DOI： 10.1186/s42466-021-00139-8

Source DB:  PubMed          Journal:  Neurol Res Pract        ISSN： 2524-3489


× No keyword cloud information.
  10 in total

1.  Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Authors:  Mathias Granqvist; Malin Boremalm; Amyar Poorghobad; Anders Svenningsson; Jonatan Salzer; Thomas Frisell; Fredrik Piehl
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

2.  Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Authors:  Christiane Gasperi; Anke Salmen; Gisela Antony; Antonios Bayas; Christoph Heesen; Tania Kümpfel; Ralf A Linker; Friedemann Paul; Martin Stangel; Björn Tackenberg; Florian Then Bergh; Clemens Warnke; Frank Weber; Heinz Wiendl; Brigitte Wildemann; Uwe K Zettl; Ulf Ziemann; Frauke Zipp; Hayrettin Tumani; Ralf Gold; Bernhard Hemmer
Journal:  JAMA Neurol       Date:  2019-07-01       Impact factor: 18.302

3.  Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.

Authors:  Anne-Laure Kaminsky; Abdou Yacoubou Omorou; Marc Soudant; Sophie Pittion-Vouyovitch; Maud Michaud; René Anxionnat; Francis Guillemin; Marc Debouverie; Guillaume Mathey
Journal:  J Neurol       Date:  2020-07-02       Impact factor: 4.849

4.  Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.

Authors:  Hajime Yano; Cindy Gonzalez; Brian C Healy; Bonnie I Glanz; Howard L Weiner; Tanuja Chitnis
Journal:  Mult Scler Relat Disord       Date:  2019-07-25       Impact factor: 4.339

5.  Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Authors:  Peter Alping; Thomas Frisell; Lenka Novakova; Protik Islam-Jakobsson; Jonatan Salzer; Anna Björck; Markus Axelsson; Clas Malmeström; Katharina Fink; Jan Lycke; Anders Svenningsson; Fredrik Piehl
Journal:  Ann Neurol       Date:  2016-04-20       Impact factor: 10.422

6.  Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.

Authors:  Ilya Kister; Tim Spelman; Francesco Patti; Pierre Duquette; Maria Trojano; Guillermo Izquierdo; Alessandra Lugaresi; Pierre Grammond; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Raed Alroughani; Murat Terzi; Cavit Boz; Raymond Hupperts; Jeannette Lechner-Scott; Ludwig Kappos; Eugenio Pucci; Suzanne Hodgkinson; Claudio Solaro; Helmut Butzkueven
Journal:  J Neurol Sci       Date:  2018-06-02       Impact factor: 3.181

7.  Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Authors:  Jonatan Salzer; Rasmus Svenningsson; Peter Alping; Lenka Novakova; Anna Björck; Katharina Fink; Protik Islam-Jakobsson; Clas Malmeström; Markus Axelsson; Mattias Vågberg; Peter Sundström; Jan Lycke; Fredrik Piehl; Anders Svenningsson
Journal:  Neurology       Date:  2016-10-19       Impact factor: 9.910

Review 8.  Definition, prevalence and predictive factors of benign multiple sclerosis.

Authors:  Tatjana Reynders; Miguel D'haeseleer; Jacques De Keyser; Guy Nagels; Marie B D'hooghe
Journal:  eNeurologicalSci       Date:  2017-05-13

9.  Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments.

Authors:  Ann Marie Weideman; Marco Aurelio Tapia-Maltos; Kory Johnson; Mark Greenwood; Bibiana Bielekova
Journal:  Front Neurol       Date:  2017-11-10       Impact factor: 4.003

10.  A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes.

Authors:  Karen K Chung; Daniel Altmann; Frederik Barkhof; Katherine Miszkiel; Peter A Brex; Jonathan O'Riordan; Michael Ebner; Ferran Prados; M Jorge Cardoso; Tom Vercauteren; Sebastien Ourselin; Alan Thompson; Olga Ciccarelli; Declan T Chard
Journal:  Ann Neurol       Date:  2019-11-22       Impact factor: 11.274
  10 in total
  2 in total

1.  Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity.

Authors:  Tobias Ruck; Sumanta Barman; Andreas Schulte-Mecklenbeck; Steffen Pfeuffer; Falk Steffen; Christopher Nelke; Christina B Schroeter; Alice Willison; Michael Heming; Thomas Müntefering; Nico Melzer; Julia Krämer; Maren Lindner; Marianne Riepenhausen; Catharina C Gross; Luisa Klotz; Stefan Bittner; Paolo A Muraro; Tilman Schneider-Hohendorf; Nicholas Schwab; Gerd Meyer Zu Hörste; Norbert Goebels; Sven G Meuth; Heinz Wiendl
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

2.  Decreased Intrathecal Concentrations of Free Light Chains Kappa in Multiple Sclerosis Patients Taking Very High Effective Disease-Modifying Treatment.

Authors:  Marie Süße; Franz Felix Konen; Philipp Schwenkenbecher; Kathrin Budde; Matthias Nauck; Matthias Grothe; Malte Johannes Hannich; Thomas Skripuletz
Journal:  Diagnostics (Basel)       Date:  2022-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.